Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Forde

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Moving Immunotherapy Into Early-Stage Lung CancerAnna Linehan, Patrick M Forde
Nature Medicine|March 17, 2023
Advancing neoadjuvant immunotherapy for lung cancerMichael Conroy, Patrick M Forde
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLCSamuel Rosner, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|August 2, 2023
Neoadjuvant immunotherapy in resectable non-small cell lung cancerSarah E Lochrin, Patrick M Forde
Endocrinology and Metabolism Clinics of North America|August 13, 2018
Lung and Thymic CarcinoidsChristine L Hann, Patrick M Forde
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2013
Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancerPatrick M Forde, Ronan J Kelly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2026
How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and AffordabilityM Raheel Khan, Patrick M Forde
Cancer Journal (Sudbury, Mass.)|July 22, 2017
Cancer Immunotherapy in Older PatientsKristen A Marrone, Patrick M Forde
Therapeutic Advances in Medical Oncology|August 27, 2025
The role of immunotherapy in resectable non-small-cell lung cancerConor D Moloney, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Managing acquired resistance in EGFR-mutated non-small cell lung cancerPatrick M Forde, David S Ettinger
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Moving Immunotherapy Into Early-Stage Lung CancerAnna Linehan, Patrick M Forde
Nature Medicine|March 17, 2023
Advancing neoadjuvant immunotherapy for lung cancerMichael Conroy, Patrick M Forde
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLCSamuel Rosner, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|August 2, 2023
Neoadjuvant immunotherapy in resectable non-small cell lung cancerSarah E Lochrin, Patrick M Forde
Endocrinology and Metabolism Clinics of North America|August 13, 2018
Lung and Thymic CarcinoidsChristine L Hann, Patrick M Forde
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2013
Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancerPatrick M Forde, Ronan J Kelly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2026
How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and AffordabilityM Raheel Khan, Patrick M Forde
Cancer Journal (Sudbury, Mass.)|July 22, 2017
Cancer Immunotherapy in Older PatientsKristen A Marrone, Patrick M Forde
Therapeutic Advances in Medical Oncology|August 27, 2025
The role of immunotherapy in resectable non-small-cell lung cancerConor D Moloney, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Managing acquired resistance in EGFR-mutated non-small cell lung cancerPatrick M Forde, David S Ettinger
Pageof 16